Literature DB >> 19074856

Disruption of crosstalk between the fatty acid synthesis and proteasome pathways enhances unfolded protein response signaling and cell death.

Joy L Little1, Frances B Wheeler, Constantinos Koumenis, Steven J Kridel.   

Abstract

Fatty acid synthase (FASN) is the terminal enzyme responsible for fatty acid synthesis and is up-regulated in tumors of various origins to facilitate their growth and progression. Because of several reports linking the FASN and proteasome pathways, we asked whether FASN inhibitors could combine with bortezomib, the Food and Drug Administration-approved proteasome inhibitor, to amplify cell death. Indeed, bortezomib treatment augmented suboptimal FASN inhibitor concentrations to reduce clonogenic survival, which was paralleled by an increase in apoptotic markers. Interestingly, FASN inhibitors induced accumulation of ubiquinated proteins and enhanced the effects of bortezomib treatment. In turn, bortezomib increased fatty acid synthesis, suggesting crosstalk between the pathways. We hypothesized that cell death resulting from crosstalk perturbation was mediated by increased unfolded protein response (UPR) signaling. Indeed, disruption of crosstalk activated and saturated the adaptation arm of UPR signaling, including eIF2alpha phosphorylation, activating transcription factor 4 expression, and X-box-binding protein 1 splicing. Furthermore, although single agents did not activate the alarm phase of the UPR, crosstalk interruption resulted in activated c-Jun NH2-terminal kinase and C/EBP homologous protein-dependent cell death. Combined, the data support the concept that the UPR balance between adaptive to stress signaling can be exploited to mediate increased cell death and suggests novel applications of FASN inhibitors for clinical use.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19074856      PMCID: PMC2641993          DOI: 10.1158/1535-7163.MCT-08-0558

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  48 in total

Review 1.  Fatty acid synthesis and its regulation.

Authors:  S J Wakil; J K Stoops; V C Joshi
Journal:  Annu Rev Biochem       Date:  1983       Impact factor: 23.643

2.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.

Authors:  T C Chou; P Talalay
Journal:  Adv Enzyme Regul       Date:  1984

3.  Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells.

Authors:  Andrew Fribley; Qinghua Zeng; Cun-Yu Wang
Journal:  Mol Cell Biol       Date:  2004-11       Impact factor: 4.272

4.  Inhibition of tumor-associated fatty acid synthase activity enhances vinorelbine (Navelbine)-induced cytotoxicity and apoptotic cell death in human breast cancer cells.

Authors:  Javier A Menendez; Ramon Colomer; Ruth Lupu
Journal:  Oncol Rep       Date:  2004-08       Impact factor: 3.906

5.  Binding site of cerulenin in fatty acid synthetase.

Authors:  H Funabashi; A Kawaguchi; H Tomoda; S Omura; S Okuda; S Iwasaki
Journal:  J Biochem       Date:  1989-05       Impact factor: 3.387

6.  A new mechanism of drug resistance in breast cancer cells: fatty acid synthase overexpression-mediated palmitate overproduction.

Authors:  Hailan Liu; Yang Liu; Jian-Ting Zhang
Journal:  Mol Cancer Ther       Date:  2008-02       Impact factor: 6.261

7.  A fatty acid synthase blockade induces tumor cell-cycle arrest by down-regulating Skp2.

Authors:  Lynn M Knowles; Fumiko Axelrod; Cecille D Browne; Jeffrey W Smith
Journal:  J Biol Chem       Date:  2004-05-11       Impact factor: 5.157

8.  The isopeptidase USP2a regulates the stability of fatty acid synthase in prostate cancer.

Authors:  Edgard Graner; Dan Tang; Sabrina Rossi; Antonella Baron; Toshiro Migita; Lisa J Weinstein; Mirna Lechpammer; Dieter Huesken; Johann Zimmermann; Sabina Signoretti; Massimo Loda
Journal:  Cancer Cell       Date:  2004-03       Impact factor: 31.743

9.  Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity.

Authors:  Steven J Kridel; Fumiko Axelrod; Natasha Rozenkrantz; Jeffrey W Smith
Journal:  Cancer Res       Date:  2004-03-15       Impact factor: 12.701

10.  Translation reinitiation at alternative open reading frames regulates gene expression in an integrated stress response.

Authors:  Phoebe D Lu; Heather P Harding; David Ron
Journal:  J Cell Biol       Date:  2004-10-11       Impact factor: 10.539

View more
  9 in total

1.  Combination Treatment with Orlistat-Containing Nanoparticles and Taxanes Is Synergistic and Enhances Microtubule Stability in Taxane-Resistant Prostate Cancer Cells.

Authors:  Joshua J Souchek; Amanda L Davis; Tanner K Hill; Megan B Holmes; Bowen Qi; Pankaj K Singh; Steven J Kridel; Aaron M Mohs
Journal:  Mol Cancer Ther       Date:  2017-06-14       Impact factor: 6.261

2.  Not4 E3 ligase contributes to proteasome assembly and functional integrity in part through Ecm29.

Authors:  Olesya O Panasenko; Martine A Collart
Journal:  Mol Cell Biol       Date:  2011-02-14       Impact factor: 4.272

3.  Lipid catabolism via CPT1 as a therapeutic target for prostate cancer.

Authors:  Isabel R Schlaepfer; Leah Rider; Lindsey Ulkus Rodrigues; Miguel A Gijón; Colton T Pac; Lina Romero; Adela Cimic; S Joseph Sirintrapun; L Michael Glodé; Robert H Eckel; Scott D Cramer
Journal:  Mol Cancer Ther       Date:  2014-08-13       Impact factor: 6.261

Review 4.  The role of sex steroid receptors on lipogenesis in breast and prostate carcinogenesis: a viewpoint.

Authors:  Henri Rochefort; Dany Chalbos
Journal:  Horm Cancer       Date:  2010-04       Impact factor: 3.869

Review 5.  Fatty acid synthase as a potential therapeutic target in cancer.

Authors:  Richard Flavin; Stephane Peluso; Paul L Nguyen; Massimo Loda
Journal:  Future Oncol       Date:  2010-04       Impact factor: 3.404

6.  Expression of Fatty Acid Synthase Depends on NAC1 and Is Associated with Recurrent Ovarian Serous Carcinomas.

Authors:  Stefanie M Ueda; Kai Lee Yap; Ben Davidson; Yuan Tian; Vivek Murthy; Tian-Li Wang; Kala Visvanathan; Francis P Kuhajda; Robert E Bristow; Hui Zhang; Ie-Ming Shih
Journal:  J Oncol       Date:  2010-05-19       Impact factor: 4.375

7.  Fatty acid synthase expression associated with NAC1 is a potential therapeutic target in ovarian clear cell carcinomas.

Authors:  M T Rahman; K Nakayama; M Rahman; H Katagiri; A Katagiri; T Ishibashi; M Ishikawa; K Iida; N Nakayama; Y Otsuki; S Nakayama; K Miyazaki
Journal:  Br J Cancer       Date:  2012-05-31       Impact factor: 7.640

8.  A minimal connected network of transcription factors regulated in human tumors and its application to the quest for universal cancer biomarkers.

Authors:  Ahmed Essaghir; Jean-Baptiste Demoulin
Journal:  PLoS One       Date:  2012-06-25       Impact factor: 3.240

9.  Novel carfilzomib-based combinations as potential therapeutic strategies for liposarcomas.

Authors:  Maya Jeitany; Aishvaryaa Prabhu; Pushkar Dakle; Elina Pathak; Vikas Madan; Deepika Kanojia; Vineeth Mukundan; Yan Yi Jiang; Yosef Landesman; Wai Leong Tam; Dennis Kappei; H Phillip Koeffler
Journal:  Cell Mol Life Sci       Date:  2020-08-26       Impact factor: 9.261

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.